Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of Pfizer Inc. (NYSE:PFE)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on March 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Pfizer stock on February 10th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Thermon Group (NYSE:THR) on 3/2/2026.
• Purchased $1,001 – $15,000 in shares of Federal Signal (NYSE:FSS) on 3/2/2026.
• Purchased $1,001 – $15,000 in shares of Taiwan Semiconductor Manufacturing (NYSE:TSM) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 2/24/2026.
• Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Oracle (NYSE:ORCL) on 2/24/2026.
• Purchased $1,001 – $15,000 in shares of Champion Homes (NYSE:SKY) on 2/23/2026.
• Sold $1,001 – $15,000 in shares of Tri Pointe Homes (NYSE:TPH) on 2/23/2026.
• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 2/20/2026.

Pfizer Trading Up 3.2%

PFE stock traded up $0.86 during mid-day trading on Tuesday, reaching $27.47. The company’s stock had a trading volume of 60,078,688 shares, compared to its average volume of 46,682,051. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The business’s 50 day moving average price is $26.53 and its 200 day moving average price is $25.54. The company has a market cap of $156.21 billion, a price-to-earnings ratio of 20.20 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company’s revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.63 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase 2 win — Pfizer said its atirmociclib + fulvestrant combo met the study’s primary endpoint, cutting risk of disease progression or death by ~40% versus control in second‑line HR+/HER2‑ metastatic breast cancer; this validates a potential successor to existing CDK4/6 drugs and bolsters oncology revenue outlook. Reuters: Pfizer says experimental breast cancer drug cuts risk of disease worsening
• Positive Sentiment: Company release and press coverage reiterate topline Phase‑2 success for atirmociclib (FOURLIGHT‑1), highlighting a statistically significant benefit versus standard regimens — a potential new growth driver if later‑stage data and regulatory steps follow. Yahoo Finance: Pfizer Announces Positive Topline Phase 2 Results
• Positive Sentiment: Analyst upgrade — HSBC raised its price target on PFE to $32 and kept a buy rating, giving an additional analyst‑driven catalyst for the stock. Benzinga: HSBC raises price target
• Positive Sentiment: Competitor setback helps Pfizer — Bicycle Therapeutics is cutting staff and deprioritizing a Padcev challenger, which lowers near‑term competitive risk for Pfizer’s fast‑selling bladder cancer franchise. BioPharmaDive: Bicycle to lay off 30% of staff
• Neutral Sentiment: Market attention & commentary — TV and market columnists (eg. Jim Cramer) are noting Pfizer’s sizable pipeline, increasing retail/institutional interest but offering no new fundamental data. Yahoo Finance: Jim Cramer Notes Pfizer
• Neutral Sentiment: Investor write‑ups (Zacks, Yahoo opinion pieces) highlight PFE as a widely followed stock — attention may lift volume but is not a direct fundamental catalyst. Zacks: Pfizer attracting attention
• Negative Sentiment: Longer‑term risks remain — commentary from retail analysts flags Pfizer’s exposure to fading COVID revenues and patent expiries; pipeline successes must scale to offset legacy revenue declines. The Motley Fool: Key risk to watch

Analysts Set New Price Targets

Several research analysts recently issued reports on PFE shares. HSBC increased their target price on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday. BMO Capital Markets reiterated an “outperform” rating and set a $30.00 price objective on shares of Pfizer in a report on Monday, March 9th. UBS Group began coverage on shares of Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective on the stock. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. Finally, Wolfe Research set a $24.00 price target on Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus price target of $28.14.

Institutional Trading of Pfizer

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PFE. Triad Wealth Partners LLC raised its position in shares of Pfizer by 1.9% in the fourth quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock worth $510,000 after buying an additional 386 shares in the last quarter. ETF Store Inc. increased its stake in Pfizer by 3.8% in the 4th quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock worth $272,000 after acquiring an additional 396 shares during the last quarter. Mattern Wealth Management LLC raised its holdings in shares of Pfizer by 4.6% in the 4th quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after acquiring an additional 400 shares in the last quarter. Pines Wealth Management LLC boosted its position in shares of Pfizer by 4.4% during the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock valued at $235,000 after acquiring an additional 400 shares during the last quarter. Finally, Peak Asset Management LLC boosted its position in shares of Pfizer by 1.4% during the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after acquiring an additional 402 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.